US2809916A - Sustained release pharmaceutical preparations - Google Patents

Sustained release pharmaceutical preparations Download PDF

Info

Publication number
US2809916A
US2809916A US541027A US54102755A US2809916A US 2809916 A US2809916 A US 2809916A US 541027 A US541027 A US 541027A US 54102755 A US54102755 A US 54102755A US 2809916 A US2809916 A US 2809916A
Authority
US
United States
Prior art keywords
produce
drying
mixing
crushing
granular material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US541027A
Inventor
Victor M Hermelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US541027A priority Critical patent/US2809916A/en
Application granted granted Critical
Publication of US2809916A publication Critical patent/US2809916A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats

Definitions

  • enteric coating is one which will resist the action of the gastric juices in the stomach and will not dissolve therein or be otherwise affected thereby so that the drug which is incorporated in the tablet will pass through the stomach and into the intestine.
  • enteric coating is of such a nature that it will be dissolved very readily in the intestinal fluid-s so that the drug which has been enclosed in the enteric coating will become effective in the intestinal tract rather than in the stomach.
  • Such tablets are merely delayed action tablets.
  • enteric coated tablet is also used when it is desirable to introduce the medicament into the pati'ents intestinal tract without discharging any of the medicament into the stomach.
  • enteric coatings are not particularly accurate and the enteric coatings now in use are not always completely reliable.
  • enteric coatings are dissolved to an appreciable extent in the gastric juices of the stomach or at least are attacked by such gastric juices to such an extent as to lose physical or structural strength, a factor which has been hitherto overlooked.
  • peristalic action is severe enough to disrupt the physically weakened enteric coating and the drum or medicament enters the system with a surge, as has been discovered by blood level studies.
  • enteric coatings however efficient or inefiicient they may be, merely withhold the medicament for some timedelay period and then release it to the patients system in the same surge dose as though the period of time delay had not occurred. In other words, the patient ultimately gets the surge.
  • *It is the primary object of the present invention, therefore, to provide a pharmaceutical preparation having a unique and novel composition and structure, which, as a result of a drug or medicament, can be administered in a persistent sustained incremental dosage.
  • V i is the primary object of the present invention, therefore, to provide a pharmaceutical preparation having a unique and novel composition and structure, which, as a result of a drug or medicament, can be administered in a persistent sustained incremental dosage.
  • a pharmaceutical preparation adapted for sustained minute-incremental dosage can be made by intimately mixing various enteric water insoluble excipients, such as shellac, with powdered drugs to form a somewhat pasty mass which is then spread on drying trays and dried to produce a rough granular material.
  • This granular material is crushed and remixed with the excipient to form a pasty mass which is then spread on trays and dried again to form .a rough granular material.
  • This procedure of crushing, mixing with excipient, and tray-drying is repeated a number of times and finally the end product is screened to produce agranular material having granules of substantially uniform size.
  • Example I enough shellac (of the,type above) until a pasty mass results. This mass is again placed on cloth drying trays .and dried, thereby again forming a granular mass as before.
  • the above procedure is repeated for a total of eleventimes, using a total of about 12 gallon of shellac (dry solids content 46%).
  • The-first four mixing-drying steps are repeated over a time cycle which involves about 7 to 10 hour drying periods and all subsequent mixing-drying steps include about 20 to 22 hour drying periods. These time periods can be speeded up by placing the drying trays in a hot room. The hot room should be maintained at about 100 to 120 F.
  • the granules are-precisely uniform in constituency. :In other words, any given weight of granules will be found 'to contain theisarne dosage of amphetamine. Of course, each-batch should be assayed and the actual amphetamine content by weight or percentage determined. It has been found that by following a standardized manufacturing procedure, successive batches of granules have closely similar assays well Within admissible limits of pharmaceutical accuracy. However,
  • Example 1 Adry mixture of .3 oz. d-arnphetamine sulfate, .12 oz. secobarbital and 3 lbs. dicalcium phosphate is taken up with Shellac as per'Example I employing approximately 1 gallon shellac in eleven successive mixing-dryingsteps.
  • Example III A dry mixture of 7 oz. pentobarbituric acid, 7 oz. phenobarbital and 2 oz. -d-amphetamine sulfate, 3 lbs. calcium carbonate is taken up in shellac as per Example I employing nine successive mixing-drying steps.
  • Example IV A. dry mixture of 2 oz. scopolamine aminoxidehydrobromide, and 5 lbs. dicalcium phosphate were taken up in shellac as per Example Iemploying-eleven successive mixing-dryingsteps.
  • Example V A dry mixture of 2 lbs. mephobarbital, 2 /2 oz. homatropine methylbromide, 1 oz. atropine methyl nitrate, /2 oz. hyoscine hydrobromide, and 6 lbs. kaolin were taken up in shellac as per Example I employing eleven successive mixing-drying steps.
  • Example VI A dry mixture of 4 lbs. mannitol hexanitrate 7% (with 13 parts lactose) was taken up in shellac as per Example I employing eleven successive mixing-drying steps.
  • Example VII A dry mixture of 3 lbs. pyralimine maleate and 1 lb. vitamin C were taken up in 60 oz. (liquid) of shellac as per Example I employing fifteen successive mixing-drying steps to produce 5.5 lbs. of finished granules. 275 mgs. of such granules were filled into a No. 3 capsule, giving a dosage of mgs. ,pyralimine maleate and 50 mgs. of vitamin C.
  • inert carriers such as calcium carbonate, tri-calcium phosphate, magnesium oxide, magnesium carbonate, kaolin, starch, or lactose, may be used. Where the drug or medicament has sufficient bulk, it-is even possible to eliminate the use of an inert carrier, as shown by Example VII.
  • liquid excipients such as a mixture of castor oil, stearic acid, and confectioners glaze (i. e. shellac), cellulose acetate phthalate in acetone, salol in alcohol, various balsams, such as tolu in alcohol, ethyl cellulose in methyl-ethylketone, or zein in isopropanol, can be employed in practicingthe herein described invention. Similarly, by'increasing-the number of.
  • mixing-drying steps it is possible to-slow down the rate of entry of the drug into the patients system and, conversely, by-lowering the number of-successive mixing-drying steps, it is possible to speed up the rate of entry of the drug into the patients system.
  • a minimum of such steps is two and a practical maximum is'fifteen, sinceadditional mixing-drying steps resulting in such a slow rate of drug absorption by the patient has beenfound to be impractical forpresently known medical purposes.
  • the granules can be placed in 'a coating pan and sugar coated with aplain or suitablycolored sugar glaze.
  • sustained period minuteincremental dosage pharmaceutical preparations which comprise intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than 3 nor more than 15 mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract
  • the process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and a water insoluble excipient consisting of a mixture of shellac and stearic acid, whereby to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing,
  • drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but 7 continuous and attenuated Solubility in the gastro-intestinal tract.
  • the process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby toreduce to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated insuccessive order, whereby to produce a pharmaceutical material consisting of granules having slow
  • the process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon air pervious trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous
  • the process for making sustained period minutemcremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon cloth bottomed trays and drying the mass slowly without agitation in such a manner as to produce :a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constitutingone cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical vmaterial consisting of granules
  • Theprocess for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce apasty mass,

Description

SUSTAINED RELEASE PHARMACEUTICA PREPARATIONS Victor M. Hermelin, University City,
No Drawing. Application October 17, 1955, erial No. 541,027
12 Claims. (Cl. 167-32) This invention relates in general to certain new and useful improvements in pharmaceutical preparations and, more particularly, to medicated granules which release the medication into the human system gradually over a sustained period of time and methods of making the same. This application is a continuation-in-part of my copending application Serial No. 461,354, filed October 11, 1954, now Pat. No. 2,736,682, which is, in turn,
United States Patent U a continuation of an earlier application Serial No.
195,369, filed November 13, 1950, now abandoned.
It has been accepted practice in the compounding of pharmaceutical tablets to provide certain types of tablets with what has been commonly referred to as an enteric coating. The enteric coating is one which will resist the action of the gastric juices in the stomach and will not dissolve therein or be otherwise affected thereby so that the drug which is incorporated in the tablet will pass through the stomach and into the intestine. The so-called enteric coating is of such a nature that it will be dissolved very readily in the intestinal fluid-s so that the drug which has been enclosed in the enteric coating will become effective in the intestinal tract rather than in the stomach. Such tablets, however, are merely delayed action tablets. In other words, by selecting an enteric coating of the proper type and by using an appropriate amount, it is possible to delay the efiective entry of the drug into the patients system for a number of hours. The so-called enteric coated tablet is also used when it is desirable to introduce the medicament into the pati'ents intestinal tract without discharging any of the medicament into the stomach. These procedures are useful in certain applications, but the patient sooner or later receives the entire dosage in a single shot, so tospeak.
, Recently, efforts have been made to provide delayed dosage by surrounding an enteric coated core with a second layer or group of layers of medicament and then, largely for appearance, covering the resulting tablet, ellipsoid or sphere with a soluble sugar coating. The theory is that the sugar coating and outer layers dissolve 'in the stomach and almost immediately release the initial dosage which lasts the patient for several hours. Meanwhile, the enteric coated core will have reached the intestinal tract and will dissolve therein very rap-' idly, releasing the second dosage. Even if this theory were borne out in practice, the net result would merely be a spaced interval two shot" medication which is very little different in therapeutic effect from the simple business of giving the patient two smaller tablets at the same intervals. As a matter of fact, however, the existing methods of forming enteric coatings are not particularly accurate and the enteric coatings now in use are not always completely reliable. The research of Maney and Kuever (J. Am. Pharm. Soc. 30, 1941, p. 276), and of Abbott and Seeport (Pharm. J. 151, 1943, p. 52), suggests that various known enteric materials yield varying *results and some such coatings seem to resist disintegration for periods up to five or sixhours. Actual tests 2,809,916 Patented Oct. 15, 1957 with various types of enteric coatings using the in vitro method of Maney and Kuever have shown that most available enteric coatings dissolved to an appreciable extent in the gastric juices of the stomach or at least are attacked by such gastric juices to such an extent as to lose physical or structural strength, a factor which has been hitherto overlooked. In the stomach, peristalic action is severe enough to disrupt the physically weakened enteric coating and the drum or medicament enters the system with a surge, as has been discovered by blood level studies. The important point, however, is that enteric coatings, however efficient or inefiicient they may be, merely withhold the medicament for some timedelay period and then release it to the patients system in the same surge dose as though the period of time delay had not occurred. In other words, the patient ultimately gets the surge.
However, recent pharmacological investigations have shown that with many drugs the patient responds far better to sustained minute-incremental dosage, that is to say, very minute quantities administered at very short intervals continuously over sustained periods of time. This can be referred to, for want of a better term, as the trickle system. Such procedures have been recognized for quite some time with respect to liquid medications such as the trickle treatment with penicillin for syphilis. The use of conventional enteric coated tablets, however, for the reason heretofore set out will not achieve even an approxiation of sustained minute-incremental dosage.
*It is the primary object of the present invention, therefore, to provide a pharmaceutical preparation having a unique and novel composition and structure, which, as a result of a drug or medicament, can be administered in a persistent sustained incremental dosage. V i
It is also an object of the present invention to provide a pharmaceutical preparation which is capable of maintaining a desired level of medication within the patients system over prolonged periods of time.
It is a further object of the present invention to provide a pharmaceutical preparation which has a unique and novel compositiohzand structure, which is simple and precise in its actionnand which is economical to produce. I 'l It is also an object of the present invention to provide methods ofmaking pharmaceutical preparations of the type stated.
With the above and other objects in view, my invention resides in the novel features of form, construction, arrangement, and combination of parts presently described and pointed out in the claims.
Broadly speaking, the present invention resides in the discovery that a pharmaceutical preparation adapted for sustained minute-incremental dosage can be made by intimately mixing various enteric water insoluble excipients, such as shellac, with powdered drugs to form a somewhat pasty mass which is then spread on drying trays and dried to produce a rough granular material. This granular material is crushed and remixed with the excipient to form a pasty mass which is then spread on trays and dried again to form .a rough granular material. This procedure of crushing, mixing with excipient, and tray-drying is repeated a number of times and finally the end product is screened to produce agranular material having granules of substantially uniform size. It has been found that, in such granules, the excipient and the medicament are intimately mixed or. dispersed throughout the mass of each granule in the form of very minute particles. Visual examination of the granules under high-magnification shows that the surface thereof is not covered with a continuous film of the dried excipient or a continuous film of the medicament, but,
rather, is dotted with minute particles of the dried excipient and minute particles of the medicament in a sort of heterogeneous arrangement. Furthermore, this general physical structure exists throughout the granule. By both in vitro tests and blood'level studies, it has been established that these granules, when in the human stomach and intestinal tract are neither soluble or insoluble in the strictest sense of these terms, but, instead, the medicament leaches out steadily in minute increments or doses, that is to say, as a sustained trickle.
While this invention is not intended to be limited thereby, the following are examples of pharmaceutical preparations which can be made in accordance with the present invention:
Example I enough shellac (of the,type above) until a pasty mass results. This mass is again placed on cloth drying trays .and dried, thereby again forming a granular mass as before. The above procedure is repeated for a total of eleventimes, using a total of about 12 gallon of shellac (dry solids content 46%). The-first four mixing-drying steps are repeated over a time cycle which involves about 7 to 10 hour drying periods and all subsequent mixing-drying steps include about 20 to 22 hour drying periods. These time periods can be speeded up by placing the drying trays in a hot room. The hot room should be maintained at about 100 to 120 F. with a relative humidity not in excess of 30% and the material dried until the granules are hard and frangible, that is to say, will :form fine-grained particles upon crushing. .Final yield is approximately 5.6 lbs. of granules of heterogeneous and irregular shapes.
Upon assay, the granules are-precisely uniform in constituency. :In other words, any given weight of granules will be found 'to contain theisarne dosage of amphetamine. Of course, each-batch should be assayed and the actual amphetamine content by weight or percentage determined. It has been found that by following a standardized manufacturing procedure, successive batches of granules have closely similar assays well Within admissible limits of pharmaceutical accuracy. However,
this is not overly important-since the granules thus formed are measured into capsules or tableted by conventional procedure for administration to the patient and any variations in drug content, as-shown'by the assay of the specific batch, can be taken into account in making up the capsule or tablet.
Example 1 1 Adry mixture of .3 oz. d-arnphetamine sulfate, .12 oz. secobarbital and 3 lbs. dicalcium phosphate is taken up with Shellac as per'Example I employing approximately 1 gallon shellac in eleven successive mixing-dryingsteps.
Yield approximately 5 /2 lbs. of granules.
Example III A dry mixture of 7 oz. pentobarbituric acid, 7 oz. phenobarbital and 2 oz. -d-amphetamine sulfate, 3 lbs. calcium carbonate is taken up in shellac as per Example I employing nine successive mixing-drying steps.
Example IV A. dry mixture of 2 oz. scopolamine aminoxidehydrobromide, and 5 lbs. dicalcium phosphate were taken up in shellac as per Example Iemploying-eleven successive mixing-dryingsteps.
Example V A dry mixture of 2 lbs. mephobarbital, 2 /2 oz. homatropine methylbromide, 1 oz. atropine methyl nitrate, /2 oz. hyoscine hydrobromide, and 6 lbs. kaolin were taken up in shellac as per Example I employing eleven successive mixing-drying steps.
Example VI A dry mixture of 4 lbs. mannitol hexanitrate 7% (with 13 parts lactose) was taken up in shellac as per Example I employing eleven successive mixing-drying steps.
Example VII A dry mixture of 3 lbs. pyralimine maleate and 1 lb. vitamin C were taken up in 60 oz. (liquid) of shellac as per Example I employing fifteen successive mixing-drying steps to produce 5.5 lbs. of finished granules. 275 mgs. of such granules were filled into a No. 3 capsule, giving a dosage of mgs. ,pyralimine maleate and 50 mgs. of vitamin C.
The above described procedure has been employed in making granules with a wide variety of drugs or medicinals, such as, for instance, scopolamine methylbromide, pentaerythritol tetranitrate, sodium nitrite, hexamethonium chloride, veratrum viride, reserpine, stilbesterol, methyl testosterone, phenobarbitol,pyralimine, digitoxin, caffeine, andantibiotics, such as penicillin,-and the like. In each instance, the quantity of the drug is calculated by usual arithmetic methods well known in pharmaceutical manufacturing. It should also be noted that, instead of dicalcium phosphate, other suitable inert carriers, such as calcium carbonate, tri-calcium phosphate, magnesium oxide, magnesium carbonate, kaolin, starch, or lactose, may be used. Where the drug or medicament has sufficient bulk, it-is even possible to eliminate the use of an inert carrier, as shown by Example VII.
It has also been found that other liquid excipients, such as a mixture of castor oil, stearic acid, and confectioners glaze (i. e. shellac), cellulose acetate phthalate in acetone, salol in alcohol, various balsams, such as tolu in alcohol, ethyl cellulose in methyl-ethylketone, or zein in isopropanol, can be employed in practicingthe herein described invention. Similarly, by'increasing-the number of. mixing-drying steps, it is possible to-slow down the rate of entry of the drug into the patients system and, conversely, by-lowering the number of-successive mixing-drying steps, it is possible to speed up the rate of entry of the drug into the patients system. However, it has been found that a minimum of such steps is two and a practical maximum is'fifteen, sinceadditional mixing-drying steps resulting in such a slow rate of drug absorption by the patient has beenfound to be impractical forpresently known medical purposes. Also, if desiredforthe sake of appearance, the granules can be placed in 'a coating pan and sugar coated with aplain or suitablycolored sugar glaze.
It is also possible tOlIlCOl'POI'flle liquid medicaments either by taking them'up in an inert carrier and ,then
granulating with shellac orother excipients as above described, or dissolving them in the liquid excipient and addingthis solution to an inert carrier to create the initial granules-and then-carrying out the repeated regranulationsusing such excipicnt solution until all-the drug bearing'excipient has been incorporated. Usually, this will take five or six mixing-drying steps. Thereafter, six to nine further successive mixing-drying steps are -em ployed using the-plain (i. e.-non-drng bearing) excipient.
It should be understood that changes and modifications intheform, construction, arrangement, and combination of the several parts of the pharmaceutical preparations maybe made and substituted-for those herein shown and described without departing from the nature-and principle of my invention.
Having thus described my invention, what I claim-and desire to secure by Letters Patent is:
if, u
L'The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and shellac to produce a pasty mass, drying the mass slowlywithout agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an addiitonal quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than 3 nor more than mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
2. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprise intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than 3 nor more than 15 mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
3. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and a water insoluble excipient consisting of a mixture of shellac and stearic acid, whereby to produce a pasty mass, drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing,
drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but 7 continuous and attenuated Solubility in the gastro-intestinal tract.
pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing opera tions constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
5. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby toreduce to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated insuccessive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
6. The process for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon air pervious trays and drying the mass slowly without agitation in such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
7. The process for making sustained period minutemcremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, spreading the mass in a thin layer upon cloth bottomed trays and drying the mass slowly without agitation in such a manner as to produce :a rough granular material, breaking up the rough granular material by light crushing, whereby to reduce it to granular particles, said mixing, drying and crushing operations constitutingone cycle, and remixing the granular particles with an additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles, said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical vmaterial consisting of granules having slow but --contin,uous and ,-attenuated solubility in the gastroint tinal. tr ct.
i8.-,'1"he process for making sustained period minuteincremental dosage pharmaceutical preparations which eomprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce a pasty mass, drying the mass slowly Without, agitation in a hot dry atmosphere in .such a manner as to produce a rough granular material, breaking up the rough granular material by light crushing, ,whereby'to reduce it to granular particles, said mixing, drying and crushing operations constituting one cycle, and remixing the granular particles ,Withan additional quantity of the excipient to produce a pasty mass, redrying such pasty mass slowly and without agitation in such a manner as to produce a granular-,material, again breaking up the rough granular material by light crushing, whereby to reduce it again to granular particles,.=said second mixing, drying and crushing operations constituting a second cycle, said process consisting of not less than three nor more than fifteen mixing, Crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract.
9. Theprocess for making sustained period minuteincremental dosage pharmaceutical preparations which comprises intimately mixing a powdered drug and an enteric water insoluble excipient to produce apasty mass,
drying-themass slowly without agitation in such a manner as to producea rough granular material, breaking up the rough granular material by light crushing, whereby t0 edu it t nu particles, s d K-. ng ;d .yins a q ush er ti n t utinsqn cyqle and maritime t nul Pa cle wi -adsi t na ua it fzth excipientto produce a pasty mass, redrying suehpasty mass slowly and-without agitation in sueh a manner as to produce a granular material, again breaking up;the rough granular material by light crushing, ,wherebyto reduce it again to granularparticles, said secondrnixing, drying and crushing operations constituting a second cycle, said process consisting of not less tha nfi nor more than 15 mixing, crushing and drying cycles repeated in successive order, whereby to produce a pharmaceutical material consisting of granules having slow but continuous and attenuated solubility in the gastro-intestinal tract, and coating the particles with asugar'glaze.
10. A pharmaceutical preparation made in-accordance with the process of claim 1.
11. A pharmaceutical preparation made in accordance with the process of claim 2.
12. A pharmaceutical preparatiommade inaecordance with the process of claim 3.
References Cited in thefile of this patent UNETED STATES PATENTS 1,012,788 Zwingenberger Dec.'2 6, 1911 2,052,376 Zellers Aug. 25, 1936 2,191,678 Nitardyet a1 Feb. 27, 1940 2,736,682 Hermelin Feb. 28, 1956 OTHER REFERENCES Little et al.: Tablet Making (Liverpool, 1949), pp. 42 and 43.

Claims (1)

  1. 2. THE PROCESS FOR MAKING SUSTAINED PERIOD MINUTE INCREMENTAL DOSAGE PHARMACEUTICAL PREPARATIONS WHICH COMPRISE INTIMATELY MIXING A POWDERED DRUG AND AN ENTERIC WATER INSOLUBLE EXCIPIENT TO PRODUCE A PASTY MASS, DRYING THE MASS SLOWLY WITHOUT AGITATION IN SUCH A MANNER AS TO PRODUCE A ROUGH GRANULAR MATERIAL, BREAKING UP THE ROUGH GRANULAR MATERIAL BY LIGHT CRUSHING, WHEREBY TO REDUCE IT TO GRANULAR PARTICLES,SAID MIXING, DRYING AND CRUSHING OPERATIONS CONSTITUTING ONE CYCLE, AND REMIXING THE GRANULAR PARTICLES WITH AN ADDITIONAL QUANTITY OF THE EXCIPIENT TO PRODUCE A PASTY MASS, REDRYING SUCH PASTY MASS SLOWLY AND WITHOUT AGITATION IN SUCH A MANNER AS TO PRODUCE A GRANULAR MATERIAL, AGAIN BREAKING UP TO ROUGH GRANULAR MATERIAL BY LIGHT CRUSHING, WHEREBY TO REDUCE IT AGAIN TO GRANULAR PARTICLES, SAID SECOND MIXING, DRYING AND CRUSHING OPERATIONS CONSTITUTING A SECOND CYCLE, SAID PROCESS CONSISTING OF NOT LESS THAN 3 NOR MORE THAN 15 MIXING, CRUSHING AND DRYING CYCLES REPEATED IN SUCCESSIVE ORDER, WHEREBY TO PRODUCE A PHARMACEUTICAL MATERIAL CONSISTING OF GRANULES HAVING SLOW BUT CONTINUOUS AND ATTENUATED SOLUBILITY IN THE GASTRO-INTESTINAL TRACT.
US541027A 1955-10-17 1955-10-17 Sustained release pharmaceutical preparations Expired - Lifetime US2809916A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US541027A US2809916A (en) 1955-10-17 1955-10-17 Sustained release pharmaceutical preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US541027A US2809916A (en) 1955-10-17 1955-10-17 Sustained release pharmaceutical preparations

Publications (1)

Publication Number Publication Date
US2809916A true US2809916A (en) 1957-10-15

Family

ID=24157898

Family Applications (1)

Application Number Title Priority Date Filing Date
US541027A Expired - Lifetime US2809916A (en) 1955-10-17 1955-10-17 Sustained release pharmaceutical preparations

Country Status (1)

Country Link
US (1) US2809916A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132067A (en) * 1960-03-31 1964-05-05 Rauscher Herbert Metal phosphide compositions and a process for their production
US3485914A (en) * 1966-07-05 1969-12-23 Chem & Pharm Patent Hold Ltd Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process
US3499959A (en) * 1966-07-05 1970-03-10 Chem & Pharm Patent Hold Ltd Therapeutic tetracycline preparation having delayed therapeutic action and processes for the production of said preparation
US4421742A (en) * 1977-02-08 1983-12-20 Dr. Werner Freyberg Chemische Fabrik Delitia Nachf. Phosphine producing pesticide and method of manufacture therefor
EP0235986A1 (en) * 1986-02-13 1987-09-09 Ethical Pharmaceuticals Limited Slow release formulation
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules
WO1995002394A1 (en) * 1993-07-13 1995-01-26 Church & Dwight Company, Inc. Co-micronized bicarbonate salt compositions
US5879714A (en) * 1996-04-24 1999-03-09 Bernard Charles Sherman Controlled-release pharmaceutical compositions
US20060147526A1 (en) * 2002-11-29 2006-07-06 Cipla Limted Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012788A (en) * 1909-04-22 1911-12-26 Otto K Zwingenberger Medicinal composition containing oil.
US2052376A (en) * 1933-05-18 1936-08-25 Edgar G Zellers Insoluble pill or tablet for internal medicinal uses
US2191678A (en) * 1938-04-02 1940-02-27 Squibb & Sons Inc Process of preparing tablets
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1012788A (en) * 1909-04-22 1911-12-26 Otto K Zwingenberger Medicinal composition containing oil.
US2052376A (en) * 1933-05-18 1936-08-25 Edgar G Zellers Insoluble pill or tablet for internal medicinal uses
US2191678A (en) * 1938-04-02 1940-02-27 Squibb & Sons Inc Process of preparing tablets
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132067A (en) * 1960-03-31 1964-05-05 Rauscher Herbert Metal phosphide compositions and a process for their production
US3485914A (en) * 1966-07-05 1969-12-23 Chem & Pharm Patent Hold Ltd Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process
US3499959A (en) * 1966-07-05 1970-03-10 Chem & Pharm Patent Hold Ltd Therapeutic tetracycline preparation having delayed therapeutic action and processes for the production of said preparation
US4421742A (en) * 1977-02-08 1983-12-20 Dr. Werner Freyberg Chemische Fabrik Delitia Nachf. Phosphine producing pesticide and method of manufacture therefor
US4600584A (en) * 1977-02-08 1986-07-15 Dr. Werner Freyberg Chemische Fabrik Delitia Nachf Phosphine producing hydrolyzable metal phosphide and use thereof
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
JPS62215519A (en) * 1986-02-13 1987-09-22 エチカル・フアーマシユーテイカルズ・リミテツド Slow release composition
EP0235986A1 (en) * 1986-02-13 1987-09-09 Ethical Pharmaceuticals Limited Slow release formulation
US4880830A (en) * 1986-02-13 1989-11-14 Ethical Pharmaceuticals Limited Slow release formulation
JPH0655669B2 (en) * 1986-02-13 1994-07-27 エチカル・フアーマシユーテイカルズ・リミテツド Sustained release composition
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules
WO1995002394A1 (en) * 1993-07-13 1995-01-26 Church & Dwight Company, Inc. Co-micronized bicarbonate salt compositions
US5879714A (en) * 1996-04-24 1999-03-09 Bernard Charles Sherman Controlled-release pharmaceutical compositions
US20060147526A1 (en) * 2002-11-29 2006-07-06 Cipla Limted Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines

Similar Documents

Publication Publication Date Title
US2809918A (en) Sustained release pharmaceutical preparations
EP0129382B1 (en) Long-acting formulation of cefaclor and its preparation
AU593038B2 (en) New drug preparation with controlled release of the active compound, a method for the manufacture thereof and the use of the new preparation
US2793979A (en) Method of making a sustained release pharmaceutical tablet and product of the method
US3922339A (en) Sustained release medicant
KR100671275B1 (en) Micronized eplerenone compositions
US3402240A (en) Medicinal tablet and process of making same
US4948581A (en) Long acting diclofenac sodium preparation
KR880002673B1 (en) Analgesic capsule
US2809917A (en) Sustained release pharmaceutical tablets
EP0255404A1 (en) Sustained release ibuprofen formulation
JPH0759500B2 (en) Diffusion coated composite unit dose
US2809916A (en) Sustained release pharmaceutical preparations
JPS62103012A (en) Multi-layered granule
US3078216A (en) Prolonged release oral pharmaceutical preparations
US3328256A (en) Spherical beads and their production
US3524910A (en) Sustained relief analgesic compositions
WO1991001734A1 (en) Prednisone microencapsulated granules
CA1216523A (en) Sustained-release product containing suloctidil
WO2008083561A1 (en) Oral pharmaceutical composition of glycyrrhizin or its salts and the preparation method thereof
US3383283A (en) Medicinal pellets coated with overlapping porous fatty acid leaflet layers
RU2451504C2 (en) Method for production of multiparticles using roller compactor
US4863741A (en) Tablet composition for drug combinations
ITMI970047A1 (en) ANTI-TUBERCULAR PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR ITS PRODUCTION
CN106924205A (en) A kind of sustained release preparation containing Baricitinib